Incorporating the assessment of abuse liability into the drug discovery and development process.
Evaluation of abuse liability is one of many obligations incurred by industrial sponsors in the development of medications acting on substrates in the central nervous system. In addition to providing the information necessary for a scheduling recommendation in the marketing application, the abuse liability assessment allows sponsors to estimate safety and commercial risks associated with scheduling, as well as to tailor their pre- and post-approval programs to collect information relevant to product misuse, illicit diversion and physical dependence. There are several important factors to consider before embarking on an abuse liability assessment, including the compound's primary and secondary biochemical activities, its absorption and metabolism, its final formulation, and its intended clinical population. Each of these factors will temper the timing and extent of the abuse liability program in animals and humans. Although every drug development program is unique in some way, a decision-making process may be applied to abuse liability assessment that will serve to better utilize limited resources and inform decisions regarding subsequent steps in the process. The emerging properties of the product will define the unique procedures best applied to assess it.
Mansbach
Robert S
RS
Worldwide Regulatory Affairs, Pfizer Global Research and Development, 50 Pequot Avenue, MS6025-B2170, New London, CT 06320, USA. mansbachrs@groton.pfizer.com
Feltner
Douglas E
DE
Gold
Lisa H
LH
Schnoll
Sidney H
SH
D000465:Algorithms; D000818:Animals; D002986:Clinical Trials as Topic; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry / Q000379:methods*; D006801:Humans; D018570:Risk Assessment; D019966:Substance-Related Disorders / Q000209:etiology / Q000517:prevention & control